United States

Drug Pricing


Britain's use of copycat biotech drugs takes off while U.S. lags

LONDON Cut-price copies of an expensive Roche biotech drug for blood cancer have taken 80 percent of the British market since launching last year, saving the healthcare system 80 million pounds ($113 million) a year, experts said on Wednesday.

Published on Oct 23, 2015

This clip features Professor Meredith Rosenthal, Dr. Aaron Kesselheim and Dr. Steven Pearson, who spoke during Drug Pricing: Public Health Implications on Friday, October 23, 2015. The event was presented in collaboration with Reuters and in association with Harvard Health Publications.

More headlines

Alexion's second rare blood disorder drug could fortify future revenue

Alexion Pharmaceuticals Inc said its experimental drug to treat a rare blood disorder showed in an eagerly awaited study that it was not inferior to its flagship drug, Soliris, paving the way for the company to establish a dominant position in the market as competition looms.

Mar 15 2018

Drug copays sometimes exceed costs

(Reuters Health) - Insurance companies may be asking people to shell out more money for drug co-payments than the drugs actually cost, a new study suggests.

Mar 13 2018

Teva rebuffs EU pay-for-delay charge at hearing

BRUSSELS Israeli drugmaker Teva rebuffed EU antitrust charges of making an illegal deal with rival Cephalon to delay selling a cheaper generic version of the latter's sleep disorder drug at a hearing on Tuesday.

Mar 13 2018

Tesla's electric motor shift to spur demand for rare earth neodymium

(This version of the March 12 story corrects year in paragraph 7, removes reference to Spectrum Rare Earths in paragraph 19)

Mar 13 2018

Newer gout drug poses risk to heart patients

Gout sufferers with major pre-existing heart disease face a higher risk of death if they are treated with the drug febuxostat, a large long-term study has concluded

Mar 12 2018

Regeneron/Sanofi heart drug succeeds in major trial; Will insurers pay?

A potent, expensive cholesterol drug sold by Regeneron Pharmaceuticals and Sanofi significantly reduced major adverse heart events in a huge study presented on Saturday but it remains to be seen whether the new data will prompt insurers to pay for increased use of the medicine.

Mar 10 2018

Regeneron/Sanofi offer new Praluent pricing to break reimbursement logjam

Regeneron Pharmaceuticals Inc and Sanofi SA said on Saturday they would be willing to charge less for their potent cholesterol drug, Praluent, if insurers agree to lessen onerous access barriers for high-risk patients.

Mar 10 2018

'Pharma Bro' Shkreli sentenced to seven years for defrauding investors

NEW YORK Martin Shkreli, the former drug company executive who made headlines by jacking up the price of a lifesaving drug before he was found guilty of defrauding investors, was sentenced to 7 years and a $75,000 fine on Friday. | Video

Mar 09 2018

Health insurer Cigna to buy Express Scripts for about $52 billion

U.S. health insurer Cigna Corp struck a $52-billion deal to buy pharmacy benefits manager (PBM) Express Scripts Holding Co on Thursday, looking for new ways to hold onto their profits as the industry faces greater scrutiny for rising healthcare costs. | Video

Mar 08 2018

Reuters Collaborations with The Forum at Harvard T.H. Chan School of Public Health


Health News


FDA moves to limit ingredients for bulk drug compounding

BOSTON The U.S. Food and Drug Administration on Friday took steps to restrict what pharmaceutical ingredients large compounding pharmacies can use to manufacture drugs in bulk that do not go through the agency's approval processes.


Trump says will sue drug companies over opioids

WASHINGTON U.S. President Donald Trump on Friday said his administration will be suing some drug companies as part of its fight against the opioid drug crisis, without giving more detail.


Pfizer's quit-smoking Chantix fails study in adolescent smokers

Pfizer Inc said on Friday its study to test safety and effectiveness of its anti-smoking treatment Chantix in adolescent smokers failed to meet the main goal.


EMA panel recommends against Portola's clot prevention drug

A panel of European Medicines Agency on Friday recommended against granting marketing approval to Portola Pharmaceuticals Inc's oral blood thinner, saying the benefits of the drug did not outweigh risks.

Top-quality nursing homes harder to access with mental health issues

(Reuters Health) - Even people with common and often treatable mental health problems like depression and anxiety may have a harder time than patients without these diagnoses getting admitted to a high-quality nursing home, a U.S. study suggests.